With cases of novel coronavirus infection rising at an alarming rate, the industry in Europe is being urged to contribute what it can by way of new products for detecting, diagnosing or treating the disease. Several research projects are also being run or started up with EU funding.
The European Medicines Agency and the European pharmaceutical industry federation EFPIA have asked companies to identify any potential vaccines or treatments they may have in their back catalogues that could be useful in tackling the ongoing novel coronavirus outbreak.
The European Commission is also offering emergency funding for research into better understanding the characteristics of 2019-nCoV and improving the...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
